Boasting a market cap of $389.21 billion, leading pharma giant Johnson & Johnson (JNJ) is all set to lift the curtains on its fourth-quarter results (ended December 2023) on January 23, 2024. Thus, this article sheds light on the fundamentals of JNJ to determine the stock’s worthiness as an investment candidate. Let’s understand in detail.
While JNJ’s third-quarter profit remained flat year-over-year, its top line, on the other hand, witnessed solid year-over-year growth. The company topped its Wall Street revenue and EPS estimates for the same quarter. Additionally, its EPS boasts an admirable track record of consistently outperforming Street estimates in each of the trailing four quarters.
